HIF-1α in colorectal carcinoma: Review of the literature
AuthorIoannou, M.; Paraskeva, E.; Baxevanidou, K.; Simos, G.; Papamichali, R.; Papacharalambous, C.; Samara, M.; Koukoulis, G.
Colorectal cancer (CRC) is the third most common cancer worldwide and despite the abundance of molecular pathways and markers continually being reported, the mortality rates remain high. Hypoxia inducible f actor lalpha (HIF-1a) plays a major role in the response of tumors to hypoxia, and contributes to tumor aggressiveness, invasiveness and resistance to radiotherapy and chemotherapy. Targeting HIF-la is an attractive strategy, with the potential for disrupting multiple pathways crucial for tumor growth. In the current study, HIF-la immunohistochemical expression in CRC is reviewed along with the relation to clinical outcome and prognosis. In addition, the significant correlation of HIF-la to vascular endothelial growth factor (VEGF) expression is reported, as well as the possible role of HIF-la in predicting the therapeutic response to anti-EGFR therapies. Herein, an overview of the HIF-la expression in CRC is presented. This review delineates the crucial role that HIF-1a plays in carcinogenesis, tumor angiogenesis and cancer progression. The evaluation of HIF-la in patient biopsies could be useful as a prognostic and/or predictive biomarker in personalized cancer treatment.